A. Hombach

U. Reinhold, H. Abken, A. Hombach, 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

T-Bodies: Antibody-Based Engineered T-Cell Receptors

Z. Eshhar, H. Abken, D. Gilham, 2014 .

Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?

U. Reinhold, S. Ferrone, H. Abken, 1998, Immunology today.

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells.

U. Reinhold, H. Abken, C. Pohl, 1997, Cancer treatment reviews.

Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

H. Abken, A. Hombach, G. Rappl, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

H. Abken, B. Giebel, A. Görgens, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells

H. Abken, A. Hombach, C. Heuser, 2003, Gene Therapy.

Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.

U. Reinhold, S. Ferrone, X. Wang, 1999, The Journal of investigative dermatology.

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

H. Abken, A. Hombach, M. Chmielewski, 2013, Human gene therapy.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

G. Schuler, G. Fey, H. Abken, 2015, Cancer Immunology, Immunotherapy.

T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.

V. Diehl, H. Abken, C. Pohl, 1997, Gastroenterology.

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells

H. Abken, Ulf Geumann, A. Hombach, 2020, Cells.

Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery.

A. Schmidt, H. Abken, C. Mauch, 2008, Rejuvenation research.

Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.

H. Abken, A. Hombach, C. Heuser, 2003, Methods in molecular biology.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.

U. Reinhold, H. Abken, C. Pohl, 1999, Hybridoma.

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

H. Abken, A. Holzinger, A. Hombach, 2013, Current molecular medicine.

Rational development of high-affinity T-cell receptor-like antibodies

V. Cerundolo, E. Jones, A. McMichael, 2009, Proceedings of the National Academy of Sciences.

T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term

H. Abken, A. Hombach, M. Chmielewski, 2012, Gene Therapy.

CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation

L. Veľas, G. Vereb, H. Abken, 2023, Frontiers in Immunology.

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer

C. Ambrose, H. Abken, P. Rennert, 2023, Cells.

CD7(-) T cells are late memory cells generated from CD7(+) T cells.

J. Becker, A. Schmidt, D. Schrama, 2008, Rejuvenation research.

IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors

H. Abken, A. Sachinidis, A. Hombach, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

H. Abken, B. Giebel, A. Görgens, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing

H. Abken, M. Krönke, H. Kashkar, 2014, Leukemia & lymphoma.

The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy.

H. Abken, A. Hombach, C. Heuser, 2002, Current gene therapy.

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

H. Abken, A. Hombach, G. Rappl, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation

H. Abken, A. Hombach, C. Heuser, 2004, Cancer Cell International.

Specific Activation of Resting T Cells Against CA19–9+ Tumor Cells by an Anti‐CD3/CA19–9 Bispecific Antibody in Combination with a Costimulatory Anti‐CD28 Antibody

V. Diehl, C. Pohl, A. Hombach, 1997, Journal of immunotherapy.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

H. Abken, A. Hombach, M. Chmielewski, 2013, Human Gene Therapy.

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.

C. Wendtner, H. Abken, L. Frenzel, 2016, Blood.

Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity.

H. Abken, A. Hombach, C. Heuser, 2003, Current pharmaceutical design.